Back to search

University of Glasgow

The L-dopa response in Parkinson's disease

Abstract

dc:description.abstract

L-dopa is the most commonly prescribed drug for the treatment of Parkinson’s disease (PD). Most patients benefit from this treatment as it can restore motor function but over time, a large proportion of patients report the manifestation of side effects. The L-dopa response is also a supportive criterion for the diagnosis of PD. This thesis aimed to explore the variation of responsiveness to L-dopa and to identify predictor variables for responsiveness. This was achieved by systematically reviewing pathological studies and case reports; analysing two large and longitudinal clinical cohort studies with focus on short- and long-term indicators of responsiveness; and the analysis of brain imaging data indicative of the degree of dopaminergic loss at different stages of the disease. The systematic review established a great variation in responsiveness to L-dopa, analysing pathologically confirmed cases where there is little to no doubt about diagnostic accuracy: 10% of definite Parkinson’s are unresponsive to L-dopa and 12% show a modest response. The clinical cohort analysis showed that current treatment management approaches lead to an overall lower prevalence of motor complications compared to earlier studies, even when L-dopa is introduced early-on. Motor fluctuations have the greatest impact on motor function but also on the patients’ abilities in everyday life situations. Investigating the short-term response showed an association of better motor function with the development of dyskinesia, and dyskinetic patients with a better response to challenge testing. Finally, SPECT imaging data showed a high residual activity of dopamine in early PD, and an association of lower putaminal uptake with higher medication doses at later stages of the disease. In conclusion, a lesser response to L-dopa should be considered as a definite phenomenon in a large proportion of PD patients. Assessing L-dopa responsiveness more widely, in clinical practice and clinical research would enhance both our understanding of patients and our interpretation of the effects of new drug treatments.

Degree

thesis:*
Level dc:type.qualificationlevel
PhD
Grantor dc:publisher.institution
University of Glasgow
Year dc:date.issued
2021

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Pitz, Vanessa

Subjects

dc:subject × 2

Rights

Language dc:language
en

Identifiers

dc:identifier.*

Chain of custody

source
Harvested from
University of Glasgow
Base URL
theses.gla.ac.uk/cgi/oai2
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
citation

Pitz, Vanessa. The L-dopa response in Parkinson's disease. PhD thesis, University of Glasgow, 2021. https://doi.org/10.5525/gla.thesis.82151